BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24487095)

  • 1. A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.
    Strassberger V; Gutbrodt KL; Krall N; Roesli C; Takizawa H; Manz MG; Fugmann T; Neri D
    J Proteomics; 2014 Mar; 99():138-51. PubMed ID: 24487095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB; Olsson L
    J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
    Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
    Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
    Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL
    MAbs; 2009; 1(5):481-90. PubMed ID: 20065652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
    Lee NK; Su Y; Bidlingmaier S; Liu B
    Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells.
    Hofmann A; Gerrits B; Schmidt A; Bock T; Bausch-Fluck D; Aebersold R; Wollscheid B
    Blood; 2010 Sep; 116(13):e26-34. PubMed ID: 20570859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
    Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
    MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
    Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
    BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of novel monoclonal antibodies for the enrichment and characterization of human corneal endothelial cells (hCENC) necessary for the treatment of corneal endothelial blindness.
    Ding V; Chin A; Peh G; Mehta JS; Choo A
    MAbs; 2014; 6(6):1439-52. PubMed ID: 25484056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.
    Callens C; Coulon S; Naudin J; Radford-Weiss I; Boissel N; Raffoux E; Wang PH; Agarwal S; Tamouza H; Paubelle E; Asnafi V; Ribeil JA; Dessen P; Canioni D; Chandesris O; Rubio MT; Beaumont C; Benhamou M; Dombret H; Macintyre E; Monteiro RC; Moura IC; Hermine O
    J Exp Med; 2010 Apr; 207(4):731-50. PubMed ID: 20368581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMMC-1, a human monoclonal antibody to fucosylated core 1 O-glycan, suppresses growth of uterine endometrial cancer cells.
    Oikawa F; Kojima-Aikawa K; Inoue F; Suzuki A; Tanaka K; Tominaga E; Aoki D
    Cancer Sci; 2013 Jan; 104(1):62-9. PubMed ID: 23035753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.
    Fatehchand K; McMichael EL; Reader BF; Fang H; Santhanam R; Gautam S; Elavazhagan S; Mehta P; Buteyn NJ; Merchand-Reyes G; Vasu S; Mo X; Benson DM; Blachly JS; Carson WE; Byrd JC; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Dec; 291(49):25656-25666. PubMed ID: 27780867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.
    Korver W; Zhao X; Singh S; Pardoux C; Zhao J; Guzman ML; Sen S; Yonkovich S; Liu S; Zhan X; Tomasevic N; Zhou C; Gros D; Jordan CT; Gotlib J; Hsi ED; Abo A
    Leukemia; 2009 Sep; 23(9):1587-97. PubMed ID: 19440216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma.
    Yan M; Yang X; Wang L; Clark D; Zuo H; Ye D; Chen W; Zhang P
    Mol Cell Proteomics; 2013 Nov; 12(11):3271-84. PubMed ID: 23903875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.